Business Context and Reporting Period
Company: ImmunityBio, Inc. (IBRX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 15, 2026
Reporting Period: Fiscal quarter and full year ended December 31, 2025
This filing announces the issuance of a press release containing preliminary, unaudited financial results for the period ended December 31, 2025. The Company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that preliminary estimates have been released in a separate press release (Exhibit 99.1) but does not contain the data itself within the 8-K body.
Material Changes
No specific material changes versus prior periods are detailed in this text. The filing explicitly states that the preliminary estimates may differ materially from the actual results that will be reflected in the consolidated financial statements for the fiscal year ended December 31, 2025, once finalized in the Annual Report on Form 10-K.
Guidance, Outlook, and Risks
- Unaudited Status: The financial results referenced are preliminary estimates based on information available as of January 15, 2026.
- Future Adjustments: Actual amounts reported in the upcoming Form 10-K will be subject to financial closing procedures and final adjustments.
- Legal Disclaimer: The information furnished pursuant to Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific preliminary financial figures.
- Monitor the upcoming Form 10-K for the year ended December 31, 2025, to verify final audited results.
- Confirm that the preliminary estimates align with the final financial closing procedures before making investment decisions.